FDA approves once-monthly injectable buprenorphine product

Dec. 1,2017

The U.S. Food and Drug Administration (FDA) this week announced it has approved a once-monthly injectable buprenorphine product for the treatment of opioid use disorder in patients who have started treatment with a sublingual film buprenorphine-containing product, such as Suboxone.  Sublocade, the once-monthly injectable, is designed for patients who have been on a stable dose of buprenorphine treatment for seven days.

Prior to its approval by the FDA, Sublocade was evaluated in two clinical studies of 848 adults with diagnoses of moderate-to-severe OUD who had begun treatment with a sublingual film buprenorphine product. Results showed patients treated with Sublocade had more weeks without positive urine tests or self-reports of opioid use, and a higher portion of patients exhibited no signs of illicit opioid use through the treatment period when compared with a placebo group.

Read the entire article at https://www.addictionpro.com/article/treatment/fda-approves-once-monthly-injectable-buprenorphine-product-0?utm_campaign=Enews&utm_source=hs_email&utm_medium=email&utm_content=59109397&_hsenc=p2ANqtz-_HEXjNErtqkoZZbyPEjs0xr-oSBC2aiypx8ah35UksnJioysivS_ccv03AEk6TBFUdUA5LZlv025KZdiI0mQR-kkOs_Q&_hsmi=59109397